TBPH

16.73

1.06% -0.18

Vorhandelsmarkt: 16.78 0.05 +0.30%

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$16.91

Offen:

$16.98

24-Stunden-Volumen:

263.40K

Relative Volume:

0.44

Marktkapitalisierung:

$861.85M

Einnahmen:

$107.46M

Nettoeinkommen (Verlust:

$105.90M

KGV:

8.2511

EPS:

2.0276

Netto-Cashflow:

$238.50M

1W Leistung:

-0.18%

1M Leistung:

+4.43%

6M Leistung:

+11.91%

1J Leistung:

+62.59%

1-Tages-Spanne:

$16.65

$17.17

1-Wochen-Bereich:

$16.45

$17.17

52-Wochen-Spanne:

$8.33

$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-14

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	16.73	861.85M	107.46M	105.90M	238.50M	2.0276
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-05	Herabstufung	Oppenheimer	Outperform → Perform
2026-03-04	Herabstufung	B. Riley Securities	Buy → Neutral
2025-12-03	Eingeleitet	Oppenheimer	Outperform
2025-09-12	Eingeleitet	B. Riley Securities	Buy
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

May 05, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire

Apr 30, 2026

Apr 28, 2026

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - FinancialContent

Apr 28, 2026

Theravance Biopharma (NASDAQ: TBPH) sets 2026 AGM votes on board, pay, auditor - Stock Titan

Apr 28, 2026

A Pivotal Quarter for Theravance Biopharma (TBPH): Milestone Cash Influx and a Transition to Pure Commercial Play - AlphaStreet

Apr 28, 2026

Apr 27, 2026

Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN

Apr 27, 2026

Apr 26, 2026

Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN

Apr 26, 2026

Apr 25, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 25, 2026

Apr 24, 2026

Laughing Water Capital Adds Theravance Biopharma to Portfolio in Q1 2026 - HarianBasis.co

Apr 24, 2026

Laughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH) - Insider Monkey

Apr 24, 2026

Laughing Water Capital’s New Position: Theravance Biopharma (TBPH) - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Theravance and Mylan settle patent dispute with Eugia Pharma - MSN

Apr 23, 2026

How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily

Apr 23, 2026

Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat

Apr 23, 2026

Apr 22, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Connect - ACCESS Newswire

Apr 22, 2026

Apr 21, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Reach Out - ACCESS Newswire

Apr 21, 2026

Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH) - Seeking Alpha

Apr 21, 2026

Apr 20, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 20, 2026

Theravance Biopharma (TBPH) Stock: What Investors Should Know (-0.75%) 2026-04-20Buy Signals - Xã Thanh Hà

Apr 20, 2026

Apr 19, 2026

B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14 - Insider Monkey

Apr 19, 2026